BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4837654)

  • 1. Fibrinolysis and thrombosis in Behçet's disease.
    Sobel JD; Tabori S; Tatarski I
    Dermatologica; 1974; 148(2):93-7. PubMed ID: 4837654
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiactivator in plasma of patients with Behçet's disease.
    Tsushima H; Toki N
    J Dermatol; 1981 Oct; 8(5):379-83. PubMed ID: 6173406
    [No Abstract]   [Full Text] [Related]  

  • 3. [Plasma coagulation and fibrinolysis parameters in patients with vascular Behçet's disease, and analysis of the multimeric structure of von Willebrand factor (vWF)].
    Kagawa H; Okubo S
    Ryumachi; 1993 Oct; 33(5):416-23. PubMed ID: 8256164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased fibrinolysis in Behçet's disease.
    Chajek T; Aronowski E; Izak G
    Thromb Diath Haemorrh; 1973 Jun; 29(3):610-8. PubMed ID: 4761829
    [No Abstract]   [Full Text] [Related]  

  • 5. [The functioning of the fibrinolytic system in Behçet's syndrome].
    Asbeck F; Meyer-Boernecke D; van de Loo J
    Verh Dtsch Ges Inn Med; 1978; (84):1359-62. PubMed ID: 741967
    [No Abstract]   [Full Text] [Related]  

  • 6. [Behçet's disease: a vascular function study by the venostasis test and DDAVP infusion].
    Le Roux G; Guillevin L; Casassus P; Gayraud M; Limon S
    Rev Med Interne; 1985 Mar; 6(2):111-5. PubMed ID: 3923585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Parameters of hemostasis in Behçet's disease].
    Dupuy E; Tobelem G; Bourgeois P; Soria C; Pellerin A; Bellucci S; Caen JP
    Rev Med Interne; 1983 Dec; 4(4):317-21. PubMed ID: 6665348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet function, blood coagulation and fibrinolysis in Behcet's syndrome.
    Stathakis NE; Economopoulos TC; Papayannis AG; Thomopoulos D
    Blut; 1977 Mar; 34(3):215-22. PubMed ID: 843627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Defective fibrinolysis in Behçet's syndrome: significance and possible mechanisms.
    Aitchison R; Chu P; Cater DR; Harris RJ; Powell RJ
    Ann Rheum Dis; 1989 Jul; 48(7):590-3. PubMed ID: 2505697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factual or artificial inhibition of fibrinolysis and the occurrence of venous thrombosis in 3 cases of Behçet's disease.
    Kluft C; Michiels JJ; Wijngaards G
    Scand J Haematol; 1980 Nov; 25(5):423-30. PubMed ID: 6452679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Blood coagulation and fibrinolysis in patients with Behçet's disease].
    Fusegawa H; Ichikawa Y; Tanaka Y; Miyachi Y; Kawada T; Gondo K; Ikeda M; Shimizu H; Arimori S; Ando Y
    Rinsho Byori; 1991 May; 39(5):509-16. PubMed ID: 2072574
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vascular involvement in Behçet's disease: relation with thrombophilic factors, coagulation activation, and thrombomodulin.
    Espinosa G; Font J; Tàssies D; Vidaller A; Deulofeu R; López-Soto A; Cervera R; Ordinas A; Ingelmo M; Reverter JC
    Am J Med; 2002 Jan; 112(1):37-43. PubMed ID: 11812405
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behçet's disease with decreased fibrinolysis and superior vena caval occlusion.
    Chajek T; Fainaru M
    Br Med J; 1973 Mar; 1(5856):782-3. PubMed ID: 4694434
    [No Abstract]   [Full Text] [Related]  

  • 14. [Blood coagulation and fibrinolytic system in Behçet's disease (author's transl)].
    Hamada T; Hosoi Y; Yoshimura R; Yamamoto S
    Nihon Hifuka Gakkai Zasshi; 1978 Sep; 88(10):615-25. PubMed ID: 309522
    [No Abstract]   [Full Text] [Related]  

  • 15. [Studies on fibrinolytic activity in Behçet's disease. 3. An approach by affinity chromatography (author's transl)].
    Saito K
    Nippon Ganka Gakkai Zasshi; 1973 Sep; 77(9):1443-51. PubMed ID: 4271707
    [No Abstract]   [Full Text] [Related]  

  • 16. Behçet's syndrome presenting as myocardial infarction with impaired blood fibrinolysis.
    Hutchison SJ; Belch JJ
    Br Heart J; 1984 Dec; 52(6):686-7. PubMed ID: 6508969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombin activatable fibrinolysis inhibitor in Behçet's disease.
    Donmez A; Aksu K; Celik HA; Keser G; Cagirgan S; Omay SB; Inal V; Aydin HH; Tombuloglu M; Doganavsargil E
    Thromb Res; 2005; 115(4):287-92. PubMed ID: 15668188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on fibrinolytic activity in Behçet's disease. II. Fibrin degradation product].
    Saito K
    Nippon Ganka Gakkai Zasshi; 1973 Jul; 77(7):693-8. PubMed ID: 4738794
    [No Abstract]   [Full Text] [Related]  

  • 19. Behçet's disease and thrombophilia.
    Leiba M; Sidi Y; Gur H; Leiba A; Ehrenfeld M
    Ann Rheum Dis; 2001 Dec; 60(12):1081-5. PubMed ID: 11709446
    [No Abstract]   [Full Text] [Related]  

  • 20. Lp(a) lipoprotein levels as a predictor of risk for thrombogenic events in patients with Behçet's disease.
    Orem A; Değer O; Memiş O; Bahadir S; Ovali E; Cimşit G
    Ann Rheum Dis; 1995 Sep; 54(9):726-9. PubMed ID: 7495343
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.